- cross-posted to:
- [email protected]
- [email protected]
- [email protected]
- cross-posted to:
- [email protected]
- [email protected]
- [email protected]
cross-posted from: https://mander.xyz/post/11304633
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
Oh, the patent expired? No problem, we’ll just methylate the structure, see that it makes no difference and put it out on the market as a new drug. Or maybe take the active part of a racemic mixture and half the dosage. Same drug double the patent. Semisynthetic insulin is even worse in that regard.